The Combination of Serum Biomarker (CA-125, FASN, and GLS) as a Predictor Suboptimal Cytoreduction in Epithelial Ovarian Cancer

2020 ◽  
Author(s):  
Gatot Nyarumenteng Adhipurnawan Winarno ◽  
Yudi Mulyana Hidayat ◽  
Setiawan Soetopo ◽  
Sofie Rifayani Krisnadi ◽  
Maringan Diapari Lumban Tobing ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Cross Sectional Study ◽  
Ca 125 ◽  
Cross Sectional ◽  
Average Value ◽  
Preoperative Serum ◽  
Serum Ca125 ◽  
Sensitivity Specificity

Abstract Purpose. Cytoreduction has an important role in improving the survival rate of epithelial ovarian cancer (EOC) patients. The use of preoperative CA-125 as an optimal predictor cytoreduction in patients with ovarian cancer is still controversial. This study aimed to assess the ability of preoperative serum CA125, FASN and GLS as a predictor of cytoreductive surgery in epithelial ovarian cancer (EOC). This observational-analytic cross-sectional study included 109 women diagnosed with epithelial ovarian cancer (EOC) between 2017-2019, who had serum CA-125, GLS, FASN measured preoperatively and underwent cytoreductive surgery. Result. The average value of serum CA-125, FASN, and GLS in the suboptimal cytoreduction were higher than the optimal cytoreduction group. The cut off point (COP) of CA-125 was 248.55 (p=0.0001) with 73.2% sensitivity and 73.6% specificity, FASN was 0.445 (p=0.017) with 62.5% sensitivity and 60.4% specificity, and GLS was 22.895 (p=0.0001) with 73.2% sensitivity and 75.5% specificity. The COP value of CA-125 and GLS combined was 29.16 (p=0.0001) with sensitivity 82.1% and spesificity 73.6%, while the COP of CA-125, GLS, and FASN combined was 0.83 (p=0.0001) with 87.5% sensitivity and 73.6% specificity. If the value of biomarker serum more than COP will more likely have suboptimal cytoreductive surgery. Conclusion. The role of CA125, FASN and GLS levels in predicting suboptimal cytoreductive surgery for patients with ovarian cancer seems questionable. However, the combination of CA-125 and GLS or CA-125, FASN and GLS are able to increase the sensitivity, specificity, and accuracy classification to predict suboptimal cytoreductive surgery.

Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer

2008 ◽  
Vol 18 (4) ◽  
pp. 621-628 ◽  
Author(s):  
A.H.M.M. ARITS ◽  
J.E.G.M. STOOT ◽  
A.A.M. BOTTERWECK ◽  
F.J.M.E. ROUMEN ◽  
A.C. VOOGD
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Preoperative Serum ◽  
Serum Ca125

scholarly journals Phosphatase Regenerating Liver3 and ECadherin Expression in Epithelial Ovarian Cancer

2017 ◽  
pp. 170-175
Author(s):  
Risma Maharani ◽  
Syahrul Rauf ◽  
Rina Masadah
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Early Stage ◽  
Cross Sectional Study ◽  
Teaching Hospitals ◽  
Advanced Stage ◽  
Cross Sectional ◽  
Exact Test ◽  
Significant Difference ◽  
E Cadherin

Objective: To determine the expression of Phosphatase Regenerating Liver-3 (PRL-3) and E-Cadherin in the epithelial ovarian cancer on various stages and differentiation grades. Method: This was a cross-sectional study design conducted at Obstetrics and Gynecology Department of several teaching hospitals, Faculty of Medicine Universitas Hasanuddin from January to June 2015. The expression of PRL-3 and E-cadherin was assessed immunohistochemically in 40 patients with epithelial ovarian cancer including 15 patients in early stage and 25 patients in advanced stage. We used the Fisher’s exact test with the significance of p0.05). The significant difference was found in the expression of E-cadherin whereas the high expression was shown at early stage than advanced stage (p0.05). This study also pointed out no correlation between the expression of PRL-3 and E-cadherin in epithelial ovarian cancer (p>0.05). Conclusion: PRL-3 overexpression does not decrease E-cadherin expression in epithelial ovarian cancer. Keywords: E-cadherin, epithelial ovarian cancer, PRL-3

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e18046-e18046
Author(s):  
Sally Anne Mullany ◽  
David S. Miller ◽  
Katina Robison ◽  
Kimberly Levinson ◽  
Yi-Chun Lee ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Study Drug ◽  
Complete Response ◽  
Submicron Particles ◽  
Ca 125 ◽  
Local Toxicity ◽  
Nonsurgical Patients ◽  
Dose Levels

e18046 Background: Although advances in chemotherapy, cytoreductive surgery, and maintenance therapy (SOC) improved PFS for high grade epithelial ovarian cancer, > 20% of patients relapse during the first 6 months and 60% relapse after 6 months. Submicron particles (~800 nm) of paclitaxel (SPP) contain 1-2 billion molecules of pure drug that release tumoricidal levels of paclitaxel over many weeks. In a previous trial, percutaneous instillations of SPP in nonsurgical patients with intraperitoneal cancer were associated with reduced systemic and local toxicity as compared to standard chemotherapy regimens. (Williamson et al Cancer Chemo Pharm (2015) 75:1075). Methods: This study compared two dose-levels of IP SPP instilled in 200 ml of saline post-cytoreductive surgery. Eligible patients with primary (n = 6) or recurrent (n = 4) epithelial ovarian cancer who underwent complete cytoreductive surgery were enrolled to receive a single instillation of IP SPP followed by standard IV carboplatin and paclitaxel. Endpoints were PFS and evaluation of treatment-emergent adverse events. Clinical response was determined by CT scans and serum CA-125 measurements. Results: Of the 24 subjects screened, 10 were enrolled and received treatment: seven patients received 100 mg/m2 and three received 200 mg/m2. For analysis purposes, 7 out of 10 subjects were evaluable (1 withdrew, 1 died unrelated to study drug during IV treatment and 1 was unevaluable). Upon completion of planned chemotherapy post-SPP instillation, the PFS at 6 months was 66% (4/6) and at 12-months 66% (4/6) using RECIST 1.1. One subject had a complete response at the end of IV treatment, but died (unrelated to study treatment) before PFS evaluation. There was one case of incision dehiscence and one case of vaginal cuff leakage after surgery. Conclusions: This pilot study supports further evaluation of IP SPP to treat peritoneal carcinomas. Clinical trial information: NCT03029585.

scholarly journals Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis

Open Medicine ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. 131-137 ◽  
Author(s):  
Junhong Guo ◽  
Jiangtao Yu ◽  
Xiaojie Song ◽  
Haixia Mi
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Diagnosis ◽  
Odds Ratio ◽  
Meta Analysis ◽  
Random Effect Model ◽  
Diagnostic Odds Ratio ◽  
Diagnostic Sensitivity ◽  
Serum Ca125 ◽  
Sensitivity Specificity

AbstractObjectiveTo evaluate the diagnostic value of combination detection of serum cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA199) and carci noembryonic antigen(CEA) in patients with epithelial ovarian cancer by pooling the open published studies according to meta-analysis method.MethodsDiagnostic studies related to combination detection of serum CA125, CA199 and CEA in patients with epithelial ovarian cancer were electronic searched in the databases of PubMed, Cochrane, Google scholar, EMBASE, ISI Web of Knowledge and CNKI by two independent reviewers. The combined diagnostic sensitivity, specificity, positive likely hood ratio (+LR), negative likely hood ratio (-LR), diagnostic odds ratio (DOR), and area under the receiver operating characteristic curve (AUC) were pooled by Med DiSc1.4 software.ResultsTwelve prospective diagnostic publications were finally fulfilled the inclusion criteria and were included in this meta-analysis. The pooled diagnostic sensitivity specificity, positive likely hood ratio, negative likely hood ratio, diagnostic odds ratio, and AUC were 0.90 (95%CI: 0.80 to 0.92), 0.83 (95%CI: 0.80 to 0.86), 5.35(95%CI:3.90 to 7.33), 0.13 (95%CI: 0.10 to 0.16), 48.53 (95%CI: 29.91 to 78.72) and 0.92 (95%C: 0.89 to 0.94) respectively by fixed or random effect model. No publication bias was found according to the funnel plot and line regression test (t=-1.34, P=0.21).ConclusionCombination detection serum CA125, CA199 and CEA was a promising biomarker forepithelial ovarian cancer diagnosis with relative high sensitivity and specificity.

scholarly journals The Prevalence of Occult Omental Metastases in Patients with Epithelial Ovarian Cancer

2018 ◽  
pp. 119
Author(s):  
Hariyono Winarto ◽  
Ken Indra
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
Obstet Gynecol ◽  
Early Stage ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Occult Metastases ◽  
Keywords Cancer

Objective: Studies regarding omentectomy on epithelialovarian cancer are scarce with conflicting results; this study isaimed to investigate the prevalence of occult metastases inpatients with epithelial ovarian cancer of the omentum.Methods: A cross-sectional study design was used by evaluating themedical records of surgically staged ovarian cancer patients in Dr.Cipto Mangunkusumo Hospital, Jakarta, Indonesia during the periodof January 2009 to December 2015.Results: A total of 51 subjects were involved in this study. One(2%) of 51 subjects was found to have occult metastases in theomentum. The prevalence of metastases of early stage epithelialovarian cancer in 2009-2015 is 33.3% (17 out of 51 subjects),whereas the omental involvement is found only in 2% subjects(1 out of 51).Conclusion: The prevalence of occult metastases of early stageepithelial ovarian cancer in Dr. Cipto Mangunkusumo Hospital,Jakarta, Indonesia, from 2009-2015 in 2% (1/51 subjects).[Indones J Obstet Gynecol 2018; 6-2: 119-122]Keywords: cancer, epithelial, metastases, omentum, ovarian cancer,ovary, prevalence

Sign in / Sign up

Export Citation Format

Share Document